Acceleron
Jul 17, 2018
Key Clinical Outcomes- 30/07/2018
AbbVie’s Orilissa for Endometriosis Pain Management Receives FDA Approval AbbVie in cooperation with Neurocrine Biosciences announced that the U.S. FDA approved Orilissa (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe e...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
